Provided by Tiger Trade Technology Pte. Ltd.

SKB BIO

472.200
-14.800-3.04%
Volume:349.28K
Turnover:164.29M
Market Cap:112.86B
PE:-285.00
High:500.000
Open:500.000
Low:459.000
Close:487.000
52wk High:581.000
52wk Low:339.600
Shares:239.00M
HK Float Shares:177.00M
Volume Ratio:0.70
T/O Rate:0.20%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.657
ROE:2.92%
ROA:-0.04%
PB:18.07
PE(LYR):-285.00
PS:46.23

Loading ...

Kelun, Merck's lung cancer combo improves survival in late-stage China trial

Reuters
·
May 22

Kelun-Biotech says sac-TMT beats chemotherapy in Phase III first-line TNBC PFS

Reuters
·
May 21

SKB BIO Shares Surge Over 5% on Positive Phase III Results for TROP2 ADC Developed with Merck

Stock News
·
May 21

Stock Track | SKB BIO Soars 5.22% Intraday on Positive Phase III Trial Results and Regulatory Approval

Stock Track
·
May 21

Movement Alert|Kelun-Biotech Biopharmaceutical Rises 3.52% in Regular Trading, TROP2 ADC Phase III Trial Achieves Dual Primary Endpoints in Endometrial Cancer

Market Focus
·
May 21

A Look At Sichuan Kelun-Biotech Biopharmaceutical’s (SEHK:6990) Valuation After New Oncology Regulatory Milestones

Simply Wall St.
·
May 20

SKB BIO Shares Surge Over 5% in Morning Session on Merck's TROP2 ADC Therapy Phase 3 Success

Stock News
·
May 19

Sichuan Kelun-Biotech Biopharmaceutical Receives NMPA Approval For IND Application For SKB118 (CR-001)

Reuters
·
May 13

Sichuan Kelun-Biotech Wins China IND Nod for Cancer Therapy

MT Newswires Live
·
May 13

SKB BIO Receives NMPA Approval for Investigational New Drug Application of SKB118

Stock News
·
May 13

SKB BIO Secures NMPA Green Light for PD-1/VEGF Bispecific Antibody SKB118; Crescent Biopharma Collaboration Advances Global Development

Bulletin Express
·
May 13

Kelun-Biotech says China regulator clears SKB118 clinical trial application

Reuters
·
May 13

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd - Receives Nmpa Approval for Ind Application for Skb118 (Cr-001) for Advanced Solid Tumors

THOMSON REUTERS
·
May 13

SKB Biopharma's Application for New Indication of Tumor Drug Accepted in China

MT Newswires Live
·
May 08

the Snda for Sacituzumab Tirumotecan (Sac-TMT) in Combination With Pembrolizumab as First‑Line Treatment for Pd-L1-Positive Nsclc Accepted for Review by Nmpa

THOMSON REUTERS
·
May 08

SKB BIO's Core TROP2 ADC Therapy Sac-TMT Gains NMPA Acceptance for New Indication Application

Stock News
·
May 08

Kelun-Biotech sac-TMT plus Keytruda NSCLC application accepted for review by China regulator

Reuters
·
May 08

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd - Nmpa Accepts New Indication Application for Sacituzumab Tirumotecan (Sac-TMT)

THOMSON REUTERS
·
May 08

3 Asian Stocks That May Be Undervalued In May 2026

Simply Wall St.
·
May 01

SKB BIO Shares Rise Nearly 3% in Late Trading as Three Studies Selected for Oral Presentation at 2026 ASCO Meeting

Stock News
·
Apr 24